LifeVantage Corporation (FRA:L2T1)

Market Cap	98.61M -29.9%
Revenue (ttm)	169.40M -12.2%
Net Income	4.99M -37.1%
EPS	0.39 -35.7%
Shares Out	n/a
PE Ratio	19.77
Forward PE	25.38
Dividend	0.16 (1.99%)
Ex-Dividend Date	Jun 1, 2026

Volume	n/a
Open	7.65
Previous Close	7.95
Day's Range	7.65 - 7.70
52-Week Range	3.20 - 12.10
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, ...

• Industry: Pharmaceutical Preparations
• CEO: Michael Beindorff
• Employees: 238
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: L2T1

Financial Performance

In fiscal year 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 15, 2026

Data Sources Report a data error